These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 24795067)

  • 21. Placebo-controlled randomized clinical trial of fish oil's impact on fatigue, quality of life, and disease activity in Systemic Lupus Erythematosus.
    Arriens C; Hynan LS; Lerman RH; Karp DR; Mohan C
    Nutr J; 2015 Aug; 14():82. PubMed ID: 26283629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: subgroup analysis of a double-blind randomized controlled trial.
    Mok CC; Ying SK; Ma KM; Wong CK
    Lupus; 2013 Dec; 22(14):1470-8. PubMed ID: 24113197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.
    Furie RA; Leon G; Thomas M; Petri MA; Chu AD; Hislop C; Martin RS; Scheinberg MA;
    Ann Rheum Dis; 2015 Sep; 74(9):1667-75. PubMed ID: 24748629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lupus Impact Tracker is responsive to physician and patient assessed changes in systemic lupus erythematosus.
    Giangreco D; Devilliers H; Annapureddy N; Block JA; Jolly M
    Lupus; 2015 Dec; 24(14):1486-91. PubMed ID: 26162686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
    Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
    J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis.
    Cheng LE; Amoura Z; Cheah B; Hiepe F; Sullivan BA; Zhou L; Arnold GE; Tsuji WH; Merrill JT; Chung JB
    Arthritis Rheumatol; 2018 Jul; 70(7):1071-1076. PubMed ID: 29513931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
    Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Roth D
    Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180
    [No Abstract]   [Full Text] [Related]  

  • 28. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
    Brunner HI; Abud-Mendoza C; Mori M; Pilkington CA; Syed R; Takei S; Viola DO; Furie RA; Navarra S; Zhang F; Bass DL; Eriksson G; Hammer AE; Ji BN; Okily M; Roth DA; Quasny H; Ruperto N
    RMD Open; 2021 Sep; 7(3):. PubMed ID: 34531304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians.
    Chang E; Abrahamowicz M; Ferland D; Fortin PR;
    J Clin Epidemiol; 2002 May; 55(5):488-97. PubMed ID: 12007552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of disease activity on health-related quality of life in systemic lupus erythematosus - a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS).
    Chaigne B; Chizzolini C; Perneger T; Trendelenburg M; Huynh-Do U; Dayer E; Stoll T; von Kempis J; Ribi C;
    BMC Immunol; 2017 Mar; 18(1):17. PubMed ID: 28351341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lupus headaches in childhood-onset systemic lupus erythematosus: relationship to disease activity as measured by the systemic lupus erythematosus disease activity index (SLEDAI) and disease damage.
    Brunner HI; Jones OY; Lovell DJ; Johnson AM; Alexander P; Klein-Gitelman MS
    Lupus; 2003; 12(8):600-6. PubMed ID: 12945718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
    Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF;
    Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of the functional assessment of chronic illness therapy-fatigue scale in patients with moderately to severely active systemic lupus erythematosus, participating in a clinical trial.
    Lai JS; Beaumont JL; Ogale S; Brunetta P; Cella D
    J Rheumatol; 2011 Apr; 38(4):672-9. PubMed ID: 21239746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunomodulatory effects of H.P. Acthar Gel on B cell development in the NZB/W F1 mouse model of systemic lupus erythematosus.
    Decker DA; Grant C; Oh L; Becker PM; Young D; Jordan S
    Lupus; 2014 Jul; 23(8):802-12. PubMed ID: 24759631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus.
    Gordon C; Wallace DJ; Shinada S; Kalunian KC; Forbess L; Braunstein GD; Weisman MH
    Rheumatology (Oxford); 2008 Mar; 47(3):334-8. PubMed ID: 18238794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
    Zhang F; Bae SC; Bass D; Chu M; Egginton S; Gordon D; Roth DA; Zheng J; Tanaka Y
    Ann Rheum Dis; 2018 Mar; 77(3):355-363. PubMed ID: 29295825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
    Fanouriakis A; Adamichou C; Koutsoviti S; Panopoulos S; Staveri C; Klagou A; Tsalapaki C; Pantazi L; Konsta S; Mavragani CP; Dimopoulou D; Ntali S; Katsikas G; Boki KA; Vassilopoulos D; Konstantopoulou P; Liossis SN; Elezoglou A; Tektonidou M; Sidiropoulos P; Erden A; Sfikakis PP; Bertsias G; Boumpas DT
    Semin Arthritis Rheum; 2018 Dec; 48(3):467-474. PubMed ID: 29555348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).
    Kalunian KC; Merrill JT; Maciuca R; McBride JM; Townsend MJ; Wei X; Davis JC; Kennedy WP
    Ann Rheum Dis; 2016 Jan; 75(1):196-202. PubMed ID: 26038091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validity of systemic lupus erythematosus disease activity score (SLE-DAS) for definition of lupus low disease activity state (LLDAS).
    Abdelhady EI; Rabie M; Hassan RA
    Clin Rheumatol; 2021 Nov; 40(11):4553-4558. PubMed ID: 34142298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study.
    Ramirez GA; Canti V; Moiola L; Magnoni M; Rovere-Querini P; Coletto LA; Dagna L; Manfredi AA; Bozzolo EP
    Int J Rheum Dis; 2019 Sep; 22(9):1752-1761. PubMed ID: 31379114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.